Trenibotulinumtoxine
As of the edition of 20 October 2026, Trenibotulinumtoxine is a protein: marketed, first approved in 2026 (CA); acts on SNAP25.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Protein
- Brand name
- Boey
- First approved
- 22 June 2026 (CA)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- AbbVie
- Registered trials
- 11, 1 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | P60880 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator and Lead sponsor of trials | 2018 to now |